---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-058505"
form_type: "8-K"
ticker: null
cik: "0000811240"
company_name: "BIOLASE, INC"
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:26:19.036015+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BIOLASE receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- On March 4, 2024, Nasdaq notified BIOLASE that its common stock closing bid price was below $1.00 for 30 consecutive business days.
- Company has 180 calendar days, until September 3, 2024, to regain compliance by achieving $1.00 close for at least 10 consecutive business days.
- If not cured by Compliance Date, may be eligible for additional 180 days if other listing standards met and a reverse stock split effected.
- Company previously received deficiency notices for stockholders' equity and market value, but was granted extension and recently found compliant on Rule 5550(b)(1).
- Company intends to monitor bid price and consider available options, including a reverse stock split if necessary.

## SEC filing metadata
- accession: 0001193125-24-058505
- form_type: 8-K
- cik: 0000811240
- company_name: BIOLASE, INC
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811240/000119312524058505/0001193125-24-058505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811240/000119312524058505/d802491d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-058505
- JSON: https://secwatch.observer/filing/0001193125-24-058505.json
- Plain text: https://secwatch.observer/filing/0001193125-24-058505.txt

## Key facts
- Listing & Compliance Notices
  BIOLASE, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 4, 2024, BIOLASE, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, ending on March 1, 2024, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until S
  evidence_url: https://www.sec.gov/Archives/edgar/data/811240/000119312524058505/0001193125-24-058505-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.